<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-131522</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Latrepirdine: a systematic review of the preclinical studies</dc:title>
<dc:description xml:lang="en">We conduct a systematic review of the preclinical studies published to date involving the use of latrepirdine (Dimebon ®). Latrepirdine is capable of modulating different targets, such as those related with mitochondria, acetylcholinesterase activity or intraneuronal calcium levels, perhaps thanks to its action upon the N-methyl-D-aspartate-type receptor, which belongs to the glutamate family. The findings published on the possible effect of latrepirdine in protein aggregation processes in disorders such as Alzheimer&#146;s disease and Parkinson&#146;s disease are quite controversial. Likewise, the possible neuroprotective effect of latrepirdine has been evaluated in animal models of neurodegenerative diseases, again with heterogeneous results. Consequently, it can be concluded that no preclinical scientific evidence has been found to justify carrying out clinical trials (AU)</dc:description>
<dc:creator>Solís García del Pozo, Julián</dc:creator>
<dc:creator>Jordán, Joaquín</dc:creator>
<dc:creator>Cano Cuenca, Nieves</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Se realiza una revisión sistemática sobre los estudios preclínicos publicados en los que se utiliza latrepirdina (Dimebon ®). La latrepirdina es capaz de modular diferentes dianas, como las relacionadas con la mitocondria, la actividad de la acetilcolinesterasa o los niveles de calcio intraneuronales, quizás gracias a su acción sobre el receptor tipo N-metil-D-aspartato, de la familia del glutamato. Los resultados publicados sobre el posible efecto de la latrepirdina en procesos de agregación proteica en trastornos como la enfermedad de Alzheimer y la enfermedad de Parkinson muestran una gran controversia. Asimismo, el posible efecto neuroprotector de la latrepirdina se ha evaluado en modelos animales de enfermedades neurodegenerativas, y muestra de nuevo resultados heterogéneos. Por todo ello, se concluye que no se ha localizado la evidencia científica preclínica que avale la realización de los ensayos clínicos (AU)</dc:description>
<dc:source>Rev Neurol;60(1): 35-42, 1 ene., 2015. ilus</dc:source>
<dc:identifier>ibc-131522</dc:identifier>
<dc:title xml:lang="es">Latrepirdina: revisión sistemática de los estudios preclínicos</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d8994</dc:subject>
<dc:subject>^d545^s22075</dc:subject>
<dc:subject>^d6792^s22079</dc:subject>
<dc:subject>^d545^s22057</dc:subject>
<dc:subject>^d6792^s22044</dc:subject>
<dc:subject>^d30561^s22073</dc:subject>
<dc:subject>^d33354^s22012</dc:subject>
<dc:subject>^d10489^s22057</dc:subject>
<dc:subject>^d6792^s22073</dc:subject>
<dc:subject>^d33354^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d10489^s22075</dc:subject>
<dc:subject>^d12256</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d12345</dc:subject>
<dc:subject>^d32116^s22073</dc:subject>
<dc:subject>^d545^s22016</dc:subject>
<dc:subject>^d35411</dc:subject>
<dc:subject>^d119^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201501</dc:date>
</metadata>
</record>
</ibecs-document>
